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BACKGROUND: Human tissue kallikrein (hK1) generates vasodilator kinins from kininogen and promotes angiogenesis by
kinin-dependent and kinin-independent mechanisms. Here, we investigate the expression and functional relevance of hK1 in human
gastrointestinal stromal tumour (GIST).
METHODS: Vascularisation and hK1 expression of GIST samples were assessed by immunohistochemistry. In two GIST cell lines, hK1
expression was assessed by PCR, and hK1 protein levels and activity were measured by ELISA and an amidolytic assay, respectively.
The effect of hK1 silencing, inhibition or overexpression on GIST cell proliferation, migration and paracrine induction of angiogenesis
was studied. Finally, local and systemic levels of hK1 were assessed in mice injected with GIST cells.
RESULTS: Human tissue kallikrein was detected in 19 out of 22 human GIST samples. Moreover, GIST cells express and secrete
active hK1. Titration of hK1 demonstrated its involvement in GIST invasive behaviour, but not proliferation. Furthermore, hK1
released by GIST cells promoted endothelial cell migration and network formation through kinin-dependent mechanisms.
Gastrointestinal stromal tumour implantation in nude mice resulted in local and systemic hK1 expression proportional to tumour
dimension.
CONCLUSIONS: Human tissue kallikrein is produced and released by GIST and participates in tumour invasion. Further studies are
needed to validate hK1 as a diagnostic biomarker and therapeutic target in GIST.
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Gastrointestinal stromal tumour (GIST) is one of the most
common mesenchymal tumours of the gastrointestinal tract, the
clinical features of which comprise acute or chronic bleeding,
altered bowel function and intestinal obstruction or perforation,
depending on the size and location of the tumour (Miettinen and
Lasota, 2006). Approximately 85–90% of GISTs harbour activating
mutations for the stem cell factor (SCF) receptor CD117 (c-Kit) or
the alpha-type platelet-derived growth factor receptor (PDGFRa)
(Heinrich et al, 2000; Hirota et al, 2000), which makes this tumour
responsive to the tyrosine kinase inhibitor imatinib mesylate
(Demetri et al, 2002). However, the mechanisms involved in the
invasive capacity of GIST remain largely unknown.
The kallikrein (hK) family has been recognised to have
fundamental roles in cancer and vascular biology (Bhoola et al,
2001; Borgono and Diamandis, 2004; Clements et al, 2004;
Madeddu et al, 2007). Individual members of the hK family have
in the past been identified as biomarkers for cancer, such as
prostate cancer-specific marker hK3 (Welch and Albertsen, 2009).
To date, no studies have investigated the involvement of hKs in the
growth and development of GIST.
Human tissue kallikrein (hK1) has a crucial role in postischae-
mic neovascularisation (Emanueli et al, 2000, 2001, 2004; Yao et al,
2008; Stone et al, 2009). Furthermore, hK1 has been implicated in
the growth and invasiveness of pancreatic carcinoma (Wolf et al,
2001), oesophageal carcinoma (Dlamini et al, 1999; Dlamini and
Bhoola, 2005), gastric malignancy (Sawant et al, 2001) and lung
cancer (Chee et al, 2008). Although the exact molecular mechan-
isms by which hK1 promotes tumour growth and invasion
have not been determined so far, two principal actions of hK1
may have a role: (1) promoting tumour cell invasion of
extracellular matrix by its protease activity, directly or through
the activation of metalloproteinases (MMPs) (Tschesche et al,
1989; Desrivieres et al, 1993; Menashi et al, 1994; Leeb-Lundberg
et al, 2005; Stone et al, 2009) and (2) activating kinin receptors,
either directly (Biyashev et al, 2006) or through the generation of
kinins (Madeddu et al, 2007). Autocrine activation of the kinin B2
receptor (B2R) on tumour cells may promote proliferation and
motility, whereas paracrine action could induce endothelial cell (EC)
proliferation and migration, thus increasing tumour vascularisation.
In this study, we aimed to investigate whether hK1 is expressed
and released by GIST and participates in tumour growth and
expansion.
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Immunohistochemistry
Formalin-fixed and paraffin-embedded GIST specimens were
obtained from the Departments of Pathology of Bristol University
(UK) and Verona University (Italy), with the approval of the local
ethics committee. Xenograft tumour samples were obtained
after excision from euthanised animals. Serial sections (3mm)
were incubated overnight with monoclonal antibodies antihuman
hK1 (1:100, R&D) and CD31 (1:40, DAKO) or Isolectin B4 (1:100,
Sigma, St Louis, MO, USA) at 41C. Immunoreactivity was detected
using the ABC method (Vector Labs, Burlingame, CA, USA) or by
applying a suitable fluorescence-labelled secondary antibody.
Normal mouse IgG (Santa Cruz, Santa Cruz, CA, USA) was used
as a negative control.
Images were taken at  200 and  400 magnification using an
Olympus light microscope (BX 40, Southall, UK). The stained area
and intensity score were evaluated in the GNU Image Manipulation
Program (GIMP) using colour selection and histogram function.
HK1 staining intensity was recalculated to a 0–100% scale, where
zero represents no staining and 100 represents the darkest (black)
area. In CD31-stained samples, vessels were expressed as the
average number of vessels per section.
GIST cell line
The immortalised GIST882 and GIST48 cell lines were a kind gift
from Dr J Fletcher (Brigham and Women’s Hospital, Boston, MA,
USA) (Tuveson et al, 2001). GIST882 was cultured in RPMI 1640
supplemented with 15% FBS, 2mML -glutamine, 100IUml
 1
penicillin and 100mgml
 1 streptomycin (Cambrex, East Rutherford,
NJ, USA). GIST48 was cultured in F10 (GIBCO) with 20% FBS, 2mM
L-glutamine, 100IUml
 1 penicillin and 100mgml
 1 streptomycin,
MITO serum extender and bovine pituitary extract (BD).
Human umbilical vein endothelial cells (HUVEC, Cambrex) were
grown in EGM-2 containing 2% FBS (Lonza, Basel, Switzerland).
Conditioned medium
Highly confluent GIST882 or GIST48 cells were incubated with
serum-free medium for 24h. After medium collection, cells were
trypsinised and counted to establish total number.
hK1 silencing
Three to five million GIST882 cells were transfected with 150nM of
small interfering RNA (siRNA) for hK1 or scrambled control
using Amaxa electroporation protocol (Amaxa Biosystems,
Gaithersburg, MD, USA). Effective silencing was verified by RT–
PCR and ELISA (see below). On-target plus siRNA was purchased
from Dharmacon (Lafayette, CO, USA).
Infection with adenoviral vector carrying hK1
GIST882 cells were incubated with 50 moi (multiplicity of
infection) of Ad.hK1 or Ad.Null overnight. Experiments were
performed 24h later. Successful infection was verified by RT–PCR
(see below). Adenoviruses were prepared as previously described
(Stone et al, 2009).
Measurement of hK1 levels and activity
Immunoreactive hK1 in cell culture supernatants and blood was
measured by ELISA as previously reported (Wang et al, 1995;
Porcu et al, 2002, 2004) and hK1 activity was assayed using the
chromogenic substrate S-2266, following the manufacturer’s
instructions (Chromogenix, Milano, Italy) and as previously
described (Madeddu et al, 1993).
Expression analysis
RNA was obtained using an RNeasy Minikit (Qiagen, Crawley, UK)
and reverse transcribed with MMLV (Invitrogen, Paisley, UK).
Real-time PCR was carried out with PCR Mastermix 2x (Promega,
Madison, WC, USA).
Primers were designed for hK1: Forward 50-GGGTCGCCACAAC
TTGTTTG-30 and Reverse 50-GCTGTAGTCCTCGTCTGCTT-30;
B1R: Forward 50-CTTCCCTCAAAATGCTACGGC-30 and Reverse
50-TCTGCCACGTTCAGTTGCC-30; B2R: Forward 50-GTCTGTTCG
TGAGGACTCCG-30 and Reverse 50-CTGGGCAAAGGTCCCGTTA
AG-30; ACE: Forward 50-AACGAAACCCACTTTGATGC-30 and
Reverse 50-TCAGCCTCATCAGTCACCAG-30; HMK: Forward
50-TGGGGCCATGAAAAACAAAG-30 and Reverse 50-CTTGGCTAG
GGAAGGGATGG-30; LMK: Forward 50-CCAGCATCTGAGAGGG
AGGT-30 and Reverse 50-GCAGAATGGGTAGGGCTGAA-30.
BrdU cell proliferation assay
Gastrointestinal stromal tumour cells were seeded in 96-well plates
(5000 cells per well) and incubated with BrdU for 24h in normal
medium or in the presence of 0.5, 0.05 or 0.005mM of specific hK1
inhibitors VA999154 or VA999024, kindly provided by Vantia Ltd.
(Chilworth, UK) BrdU incorporation was determined following the
manufacturer’s protocol (Roche, Melwin, UK).
GIST invasion assay
The invasion capacity of GIST882 and GIST48 cells was measured
by seeding 5 10
4 cells on top of an 8mm filter coated with
Matrigel (BD, 1:100). Medium containing 5% FBS was used as a
stimulus. hK1 inhibitors VA999154 and VA999024 were added at a
concentration of 0.5mM as described above. After 24h, the filters
were mounted with DAPI to recognise the nuclei of migrated cells.
Cell number was calculated by averaging the counts of five
microscopic fields (photographed at  20).
Endothelial cell migration assay
The migratory response of ECs to GIST was assessed in a transwell
array (Corning, Corning, NY, USA). Briefly, 3 10
5 GIST882 cells
were plated on the bottom chamber of the migration system. Human
umbilical vein ECs (HUVECs) were preincubated with B1Ro rB 2R
antagonists (Lys-des-Arg
9Leu
8-BK, LdL-BK or Icatibant, IC, respec-
tively, 2 10
 7M) or PBS (vehicle), plated on top of the insert (50000
cell per insert) and then left to migrate overnight in the presence or
absence of B1Ro rB 2R antagonists. Migrated HUVECs were counted
as described for the invasion assay and the percentage of migrated
cells was calculated on the number of plated cells.
Matrigel angiogenesis assay
HUVECs pretreated for 30min with the hK1 inhibitor kallistatin
(1mM, R&D) (Wolf et al, 1999), the serine protease inhibitor
Aprotinin (50Uml
 1, Bayer, FRG) or vehicle were plated on
growth factor-reduced Matrigel (BD Biosciences, Erembodegem,
Belgium) in the presence of GIST882-conditioned medium or
unconditioned medium (as a control). Total tube length and
average tube thickness were measured on photographs captured
at 24h and analysed using ImagePro Plus software (Media
Cybernetics, Bethesda, MD, USA).
FACS analysis
Cells were incubated with rabbit polyclonal antibodies for B1Ra n dB 2R
(1:100, Sigma), followed by FITC-labelled antirabbit secondary
antibodies (Sigma) and analysed in a FACScalibur (BD Biosciences)
flow cytometer. Controls were stained with isotype control.
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The experiments involving mice were conducted in accordance
with the Guide for the Care and Use of Laboratory Animals
prepared by the Institute of Laboratory Animal Resources and with
previous approval of the UK Home Office and the University of
Bristol ethics committee.
GIST882 cells were implanted under the dorsal skin of BALB/c
nude mice in three doses (3 10
6-3M, 5 10
6-5M and 8  10
6-8M
cells or vehicle; four mice per dosage). Tumour growth was
monitored biweekly. All mice were euthanised with an excess of
anaesthesia when the tumour size of the highest-dose group
reached 16mm
3. Before being killed, blood was collected by
cardiac puncture and tumour tissue was collected for further
analysis.
Statistical analysis
Continuous variables were compared by one-way ANOVA or
Student’s t-test as appropriate. Relationships between variables
were determined by the Pearson correlation coefficient. Contin-
uous data are expressed as mean±s.e.m. A P value o0.05 was
considered statistically significant. Analyses were performed with
GraphPad Prism 5.0 (Graphpad software, La Jolla, CA, USA).
RESULTS
High circulating levels of hK1 in a GIST patient
We previously reported that hK1 levels are remarkably elevated in
peripheral blood of patients with critical carotid artery obstruction
and normalised after endarterectomy (Porcu et al, 2004). Only one
subject of this series showed persistently high hK1 levels before
and after revascularisation (1456 and 1681pgml
 1, respectively).
The patient was referred to us 8 months after endarterectomy
because of the appearance of constipation. Computerised tomo-
graphy scanning documented a solid mass (7 6cm diameters)
infiltrating the ileum and reaching the abdominal wall (Figure 1A).
At power Doppler, the mass appeared irregularly perfused
(Figure 1B). Surgical resection resulted in a remarkable reduction
of circulating hK1 (368pgml
 1, 2 months after surgery).
Histological examination of the mass revealed the characteristics
of mixed spindle and epithelioid cell GIST, positive for c-Kit and
negative for S-100 protein, glial fibrillary acidic protein (GFAP),
desmin and CD34 (not shown). Vascular cells (EC) and GIST cells
were positive for hK1 (red arrows, Figure 1C). The vascular
endothelium was identified in consecutive sections by positive
staining for von Willebrand factor (Figure 1D). Specificity of
the reaction was confirmed by parallel staining of hK1-producing
salivary glands and GIST specimens (Figure 1E and F).
*
Figure 1 Clinical case. Representative CT scan images showing the presence of a tumour mass, highlighted by an asterisk, in the abdominal cavity (A).
The mass appears irregularly perfused, as shown by Doppler imaging (B). Immunohistochemistry analysis confirmed typical GIST characteristics and
expression of hK1 (red arrows) in tumour cells (C) and vasculature (D, stained with von Willebrand). Specificity of the hK1 staining was confirmed on
sections of salivary glands (E, positive control) and GIST incubated with mouse IgG (F, negative control). Biopsies derived from normal gastrointestinal tract
reveal no expression of hK1 in either the epithelial layer (dashed line) or in the muscular area (continuous line) (G). Scale bar: 100mm.
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aberrant expression of hK1 by GIST (Figure 1G).
Retrospective analysis of hK1 expression in GIST
We verified the expression of hK1 in a series of 22 GIST cases.
Patient characteristics are summarised in Table 1, which also
reports tumour localisation and risk of aggressive behaviour as
proposed by Fletcher et al (Fletcher et al, 2002). Immuno-
histochemistry revealed that 19 of 22 GIST cases were positive for
hK1 with variable intensity and percentage of positive tissue
(representative microphotographs in Figure 2A and B).
Quantitative assessment of hK1 expression was performed by
measuring (1) the section area positive for hK1 in relation to the
total section area and (2) the intensity of the staining (Figure 2C
and D). As shown in Figure 2E, ANOVA detected a difference in
hK1 expression with regard to the tumour location (P¼0.02), with
largest positive areas in small intestine samples (18.6±4.7% of
total section), followed by the stomach (9.1±2.4%) and rectum
(2.9±2.2%). In contrast, hK1 expression was independent of the
risk index or cellular type (Figure 2F and G). Furthermore, no
correlation was found with the tumour vascular density, adjusting
for age, sex, tumour cellular type, location and risk index.
GIST cell lines express hK1
Two different GIST cell lines were analysed for hK1 expression
using RT–PCR and ELISA. Both Imatinib-sensitive GIST882 cells
and Imatinib-resistant GIST48 express hK1 mRNA and protein. In
particular, GIST882 cells release 30–400pgml
 1 and GIST48 cells
about 40pgml
 1 of immunoreactive hK1 into the culture medium.
Furthermore, the exposure of GIST882 cells to hypoxia and serum
deprivation increased hK1 mRNA levels (Figure 3A) and
immunoreactive hK1 content in the culture medium (Figure 3B).
To verify that secreted hK1 is enzymatically active, GIST882
supernatants were assayed using a colorimetric assay for hK1 in
the presence or absence of the serine protease inhibitor aprotinin
Table 1 Patients and tumours characteristics
Number of cases 22
Average age (years) 60±2
Sex
Male 11
Female 11
Location
Stomach 13
Small bowel 7
Rectum 2
Risk level
Low 5
Intermediate 9
High 8
Main cell type
Spindle 13
Epithelioid 8
Mixed 1
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Figure 2 Immunohistochemical localisation of hK1 in human GIST samples. Microphotographs show strong cytoplasmatic staining for hK1 in the tumour tissue
in both spindle-shaped (A) and epithelioid cells (B). Scale bar: 100mm. For each section, the area positive for hK1 was selected and the ratio between the pixels
of the selected area and total number of pixels was calculated (in the example, 733116/1447680 100¼56%). Histograms show the analysis of corresponding
images. Average colour intensity in the selection was considered as staining intensity (median¼70 in the bottom right histogram C and D). Scatterplot graphs
showing the relationship between the calculated expression of hK1 and GIST localisation (E), risk (F)a n dc e l lt y p e( G). Each dot represents a GIST case.
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the presence of inhibitable enzymatic activity in GIST882 super-
natants (Figure 3C). Lower levels of hK1 expression detected in
GIST48 supernatants were not sufficient for the enzymatic activity
quantification (not shown). Levels of hK1 mRNA and protein
could be efficiently inhibited using siRNA (Figure 3D and E).
Effect of hK1 on GIST882 cell function
Human tissue kallikrein might be implicated in GIST growth and
invasiveness through an autocrine mechanism mediated by kinin
receptors, as well as through promotion of extracellular matrix
degradation.
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Figure 4 Human tissue kallikrein is implicated in the invasive capacity of GIST cells. Gene silencing by sihK1 or forced expression of hK1 by Ad.hK1
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strated the absence of B1R and B2R protein and mRNA in GIST882
cells. Furthermore, GIST882 cells do not express kininogens or the
kinin-degrading enzyme angiotensin-converting enzyme (ACE).
Conversely, GIST48 showed expression of both receptors and ACE
(Figure 3H). These data indicate that, although hK1 is the only
component of the kallikrein–kinin system expressed by GIST882
cells, therefore excluding kinin receptor-mediated autocrine
mechanisms in these tumoural cells, GIST48 might respond
directly to hK1.
The effect of changes in hK1 expression on GIST882 cell
functional properties was then studied using siRNA-mediated
silencing, inhibition by VA999154 and VA999024, or adenovirus-
mediated hK1 gene transfer. Efficient transduction after gene
transfer was confirmed by ELISA showing a 3 10
3-fold increase
in hK1 levels compared with Ad.Null (data not shown).
A very small effect of hK1 silencing on GIST882 proliferation
was detected (Figure 4Ai), but not confirmed, by pharmacological
inhibition (Figure 4Aii). Similarly, a very small, but significant
increase in GIST882 proliferation following hK1 transduction was
observed (Figure 4Aiii). Pharmacological inhibition of hK1 did not
exert significant effects on GIST48 proliferation (data not shown).
Silencing of hK1 significantly decreased, whereas hK1 over-
expression tended to increase GIST882 cell invasive capacity
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s(Figure 4Bi and Bii). Pharmacological inhibition of hK1 reduced
both GIST882 and GIST48 invasiveness, suggesting that hK1 might
be involved in GIST dissemination (Figure 4Biii and Biv).
Endothelial cell migration towards GIST is mediated by
kinin receptors
Previous studies highlighted the role of endogenous and transgenic
hK1 in the promotion of angiogenesis (Emanueli et al, 2000, 2001;
Stone et al, 2009). Here, we assessed whether GIST-released hK1
may exert a proangiogenic action on HUVEC, thus supporting an
attractive effect on host vessels.
Exposure of HUVECs to GIST882-conditioned medium inc-
reased B2R mRNA expression by four-fold, and B1R by two-fold
(Figure 5A and B). In a transwell migration assay, GIST882 cells
strongly attracted HUVECs. Addition of B1Ro rB 2R antagonists
had only a mild effect on HUVEC migration, whereas a 25%
inhibition was obtained with the combination of both compounds
(Figure 5C). These data suggest that B1R and B2R are involved in
GIST-induced HUVEC migration.
We then verified whether GIST882-conditioned medium has a
stimulatory action on HUVEC network formation capacity in the
Matrigel assay. We found that GIST882-conditioned medium
stimulated the formation of wider branches, with this effect being
inhibited by aprotinin, the hK1 inhibitor kallistatin and, to a minor
extent, the combination of B1R and B2R antagonists (Figure 5D). In
contrast, GIST882-conditioned medium did not influence the
cumulative length of branches (Figure 5E). These results indicate
that hK1 secreted by GIST contributes to endothelial migration
and promotes vascular stabilisation.
Local and systemic expression of hK1 in mice with
xenogeneic GIST graft
Finally, we tested whether xenogeneic GIST882 cell grafts in nude
mice reproduce the phenotype observed in GIST-bearing patients,
for example, local expression of hK1 and high hK1 circulating
levels.
To this aim, three escalating GIST882 cell dosages (3 10
6,
5 10
6 and 8 10
6) or vehicle was implanted under the skin of
BALB/c nude mice. Tumour growth was directly proportional to
the number of injected cells, with the lowest cell dosage (3 10
6)
barely forming identifiable nodules (Figure 6A). Similarly,
circulating levels of hK1 increased in tumour-bearing mice in
proportion to tumour size, being detectable even in the smallest
dosage of GIST882 cells (Figure 6B). Tumours were explanted from
mice given 5 10
6 or 8 10
6 GIST882 cells and subjected to
verification of hK1 expression by ELISA and immunohisto-
chemistry. Enzyme-linked immunosorbent assay revealed high
levels of hK1 in the examined tumours (Figure 6C). Immunohis-
tochemistry confirmed the cytoplasmatic staining for hK1 as
observed in human GIST sections (Figure 6D). In particular, hK1
was expressed in the central core and the peripheral part of the
tumour. Analysis of tumour vasculature identified host vessels
invading the periphery of the xenograft (Figure 6E).
DISCUSSION
A significant number of adenocarcinomas express hKs. These
tumours likely take advantage of hKs enzymatic properties to
influence growth and metastasis (Borgono and Diamandis, 2004).
Despite its early discovery, association of hK1 with cancer was late
in comparison with other members of the hK family. A previous
study showed the expression and localisation of hK1 in pancreatic
adenocarcinoma of ductal origin and in a breast cancer cell line
(Wolf et al, 2001). To the best of our knowledge, this is the first
documentation that GISTs, the most common mesenchymal
tumour of the gastrointestinal tract, express and release hK1 into
the surrounding environment and circulation. The reason for this
aberrant expression remains unknown. HK1 expression is
responsive to oestrogens (Madeddu et al, 1991); however, we
could not find a gender-related difference in hK1 levels in the
GISTs of our series. Furthermore, hK1 levels were not associated
with the cellular type and indexes of aggressiveness. An association
was instead found with tumour location, with the highest values in
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sGISTs of the small intestine. Our in vitro data show that expression
levels in the GIST cell line are increased by hypoxia/starvation,
pointing to the possibility that areas of the tumour far away from
the vasculature could be stimulated to produce larger amounts of
hK1. This is, at least in part, in line with the prevalent localization
of hK1 in the central avascular core of GIST882 xenografts.
In vitro studies on two different cell lines derived from Imatinib-
resistant or Imatinib-sensitive tumours showed the common
expression of hK1. Cell biology results suggest two distinct
molecular mechanisms by which hK1 could be implicated in
GIST growth: (1) invasion through degradation of the ECM and
(2) induction/stabilisation of host-derived tumour vasculature.
A direct action of hK1 as an ECM-degrading enzyme could
be complemented by the ability of hK1 to cleave and activate
other proteases, such as pro-MMPs (Menashi et al, 1994). The
proinvasive action was verified by a gene titration approach, using
siRNA to decrease native hK1 expression and Ad.hK1 to force hK1
production. Silencing resulted in inhibition of GIST invasive
capacity and overexpression enhanced it. The effect of silencing
was further confirmed using inhibitors of hK1 activity. It is
therefore likely that changes in hK1 production, release and
clearance by endogenous inhibitors may confer a different invasive
profile to the tumour.
Coculture experiments showed that GIST882 cells exert an
attractive action on HUVEC, which is at least in part due to
activation of kinin receptors, as verified by the use of receptor
antagonists. Furthermore, GIST882-conditioned medium stimu-
lates HUVEC to form more robust branches than those observed
using unconditioned medium. The fact that kallistatin, which
rapidly binds hK1 and inhibits its activity in vitro (Zhou et al,
1992), blocks the strengthening action of GIST882 cells on HUVEC
networks argues in favour of hK1 as a promoter of cancer
angiogenesis. Kallistatin itself was previously identified as an
inhibitor of angiogenesis in gastric carcinomas (Zhu et al, 2007). In
the retrospective analysis of human GISTs, we could not find any
correlation between hK1 expression and vascular density, suggest-
ing that other mechanisms may overwhelm or confound the
proangiogenic effect of hK1 in vivo. On the other side, although
HUVECs are widely used as models for tumoural angiogenesis,
different mechanisms might drive cancer endothelial cells.
In conclusion, results of our study show for the first time that
hK1 is implicated in GIST invasion and angiogenesis. GIST882
xenografts express and release hK1 into the circulation, a result
that calls for further validation of hK1 as a potential diagnostic
biomarker. On a therapeutic standpoint, hK1 inhibitors showed
promising results in models of breast cancer invasion (Wolf et al,
2001). Combination therapies incorporating hK1 inhibition/silen-
cing as adjuvant to imatinib mesylate therapy may be useful for the
treatment of GIST.
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